Related references
Note: Only part of the references are listed.Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect
Inigo San-Millan et al.
CARCINOGENESIS (2017)
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm
Suchita Pakkala et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches
J. Remon et al.
LUNG CANCER (2017)
Prostate cancer, PI3K, PTEN and prognosis
Helen M. Wise et al.
CLINICAL SCIENCE (2017)
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies
Bingliang Fang
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
Targeting the Mammalian Target of Rapamycin in Lung Cancer
Glenn W. Vicary et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)
The therapeutic potential of mTOR inhibitors in breast cancer
Linda S. Steelman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
AKT in cancer: new molecular insights and advances in drug development
Prabhjot S. Mundi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Combinational strategies of metformin and chemotherapy in cancers
Hui-Hui Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Transforming Cancer Prevention through Precision Medicine and Immune-oncology
Thomas W. Kensler et al.
CANCER PREVENTION RESEARCH (2016)
MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Nora Rauch et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2016)
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
Ryota Kurimoto et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
Carly C. Barron et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase
Qianqian Guo et al.
MOLECULAR MEDICINE REPORTS (2016)
Molecular targets of metformin antitumor action
Stanislaw Sosnicki et al.
PHARMACOLOGICAL REPORTS (2016)
Metformin: An anti-diabetic drug to fight cancer
Marie Daugan et al.
PHARMACOLOGICAL RESEARCH (2016)
Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence
Silvio De Flora et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
The impact of metformin and salinomycin on transforming growth factor -induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines
Stefan Koeck et al.
ONCOLOGY LETTERS (2016)
Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL-induced apoptosis
Uddin M. D. Nazim et al.
ONCOTARGET (2016)
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
Li Li et al.
ONCOTARGET (2016)
Repurposing metformin for cancer treatment: current clinical studies
Young Kwang Chae et al.
ONCOTARGET (2016)
Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
Hongxin Cao et al.
SCIENTIFIC REPORTS (2016)
Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
Jenny J. Lin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study
Rana Sayed et al.
Asian Pacific Journal of Cancer Prevention (2015)
β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells: the role of Sp1
ShunYu Zhao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin
Dong Suwei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again
Ashish Saxena et al.
ONCOLOGIST (2015)
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Shingo Eikawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria-mediated pathway
Junling Wang et al.
ONCOLOGY LETTERS (2015)
GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo
Adele Chimento et al.
ONCOTARGET (2015)
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
Li Li et al.
ONCOTARGET (2015)
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
Floris H. Groenendijk et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
Igor Vujic et al.
ONCOTARGET (2015)
Reduced Risk of Lung Cancer With Metformin Therapy in Diabetic Patients: A Systematic Review and Meta-Analysis
Zhi-Jiang Zhang et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2014)
PI3K/AKT signaling pathway and cancer: an updated review
Miriam Martini et al.
ANNALS OF MEDICINE (2014)
Anti-Diabetic Medications Do Not Influence Risk of Lung Cancer in Patients with Diabetes Mellitus: a Systematic Review and Meta-analysis
Shu-Ping Nie et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Li Li et al.
CLINICAL CANCER RESEARCH (2014)
Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth
Swei Sunny Hann et al.
MOLECULAR CANCER (2014)
Targeting RAS-ERK signalling in cancer: promises and challenges
Ahmed A. Samatar et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis
Zhongquan Zhao et al.
PLOS ONE (2014)
Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase
Yajun Wang et al.
ONCOLOGY LETTERS (2014)
Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status
Zhiguang Xiao et al.
ONCOTARGET (2014)
Non-small-cell lung cancers: a heterogeneous set of diseases
Zhao Chen et al.
NATURE REVIEWS CANCER (2014)
Metformin Enhances Cisplatin Cytotoxicity by Suppressing Signal Transducer and Activator of Transcription-3 Activity Independently of the Liver Kinase B1-AMP-Activated Protein Kinase Pathway
Chien-Chung Lin et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2013)
LKB1/AMPK/mTOR Signaling Pathway in Non-small-cell Lung Cancer
Dong Han et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and Excision Repair Cross-Complementation 1 Expression in Non-Small Cell Lung Cancer Cells
Jen-Chung Ko et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2013)
Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel
Sheng-Chieh Tseng et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Targeting LKB1 signaling in cancer
S. E. Korsse et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK
Y. Storozhuk et al.
BRITISH JOURNAL OF CANCER (2013)
Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
Brendan J. Quinn et al.
CANCER PREVENTION RESEARCH (2013)
Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2013)
Metformin in lung cancer: rationale for a combination therapy
Floriana Morgillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line
Satoru Kitazono et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Metformina sinergicamente potencializa os efeitos antiproliferativos de cisplatina e etoposideo em linhagem de celulas de cancer humano de pulmao NC1-H460
Sarah Fernandes Teixeira et al.
JORNAL BRASILEIRO DE PNEUMOLOGIA (2013)
K-ras gene mutation as a predictor of cancer cell responsiveness to metformin
Yu Ma et al.
MOLECULAR MEDICINE REPORTS (2013)
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells
Jen-Chung Ko et al.
LUNG CANCER (2013)
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Monica Franciosi et al.
PLOS ONE (2013)
Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways
Minh Truong Do et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II
Barbara Salani et al.
SCIENTIFIC REPORTS (2013)
Antidiabetes Drugs Correlate With Decreased Risk of Lung Cancer: A Population-Based Observation in Taiwan
Shih-Wei Lai et al.
CLINICAL LUNG CANCER (2012)
Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells
Barbara Salani et al.
FASEB JOURNAL (2012)
Metformin in cancer: translational challenges
Ryan J. O. Dowling et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2012)
Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
William D. Travis
MODERN PATHOLOGY (2012)
Metformin and cancer: new applications for an old drug
Taxiarchis V. Kourelis et al.
MEDICAL ONCOLOGY (2012)
Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Hiroshi Noto et al.
PLOS ONE (2012)
Metformin and neoplasia: Implications and indications
Ahmad Aljada et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Prognostic Influence of Metformin as First-Line Chemotherapy for Advanced Nonsmall Cell Lung Cancer in Patients With Type 2 Diabetes
Ben-Xu Tan et al.
CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT) From cancer stem cells to aging-associated fibrosis
Silvia Cufi et al.
CELL CYCLE (2010)
Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?
Issam Ben Sahra et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation
Rosa Sirianni et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2010)
Roles for Growth Factors in Cancer Progression
Esther Witsch et al.
PHYSIOLOGY (2010)
K-ras mutations in non-small-cell lung carcinoma:: A review
Sarit Aviel-Ronen et al.
CLINICAL LUNG CANCER (2006)
Metformin and reduced risk of cancer in diabetic patients
JMM Evans et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Diabetes and the risk of lung cancer
GC Hall et al.
DIABETES CARE (2005)
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
E Raymond et al.
DRUGS (2000)
Share Paper
